Who is the partner of Sinopharm? Sinopharm’s vaccine is at Phase III and they started the Stage 3 testing since June 2020. We could see the final approval come in anytime soon.
Why Titijaya agreement with Sinopharm requires Titijaya to build “Purpose-built Medical Base” for Sinopharm?????
Anyway, agree operator may press down prices to squeeze weak holders, especially those with a lot of profit.... let’s see how low they can press down and I believe many are waiting to collect haha
Frienship, I think Khairy statement signified that the politicians are also jumping on the healthcare bandwagons. So the game is getting more complicated and not so straightforward as not just anyone can join in the vaccine biz sesuka hati. You gonna need the right political alignment to be in the game.
I think there is licensing issue to deal with here. Its easy to get license to sell general medical products such as gloves, masks and medical accessories and equipments. But with vaccine, the licensing would be very strict and controlled. Dr Hisham recently said Msia Govt is talking directly with China Govt and vaccine players in regards to the manufacturing and supply of the vaccines once they become available. So it would seemed that the Govt is formulating a certain plan on the procurement, supply and distribution of the vaccine. So the question is, would any private entities be given license to be involved?
Whatever plans our government has, if they want to get Sinopharm vaccine, Titijaya has signed exclusive agreement with Sinopharm, so please talk to Titijaya
To me, Titijaya is probably be the biggest hidden Gem in Bursa now. Price also safe as it just started to move up and downside risk is lesser compared to other glove or vaccine counters which already went up 300-1000%
Titijaya property business NTA is 0.86 and now with the new business diversification profit is expected to rise further and even without vaccine play, current price is already a good bargain
Buy Titijaya now is low downside risk with huge upside potential
Need to hold mid to long term. If really can contribute up to 25% total net profit.. This is no small biz..
The Board anticipates that the net profit attributable to the New Business may contribute more than 25.0% of the total net profit of Titijaya Group in the financial years moving forward.
+++++++++++++++
Pursuant to the Strategic Collaboration Agreements, the respective responsibilities and the contributions from each parties are set out below:- Strategic Collaboration Agreement I TRSB and SMEQ shall be exclusively responsible and to develop the New Business as set out in the Strategic Collaboration Agreement I in their specified territory as follows:- TRSB: Malaysia, Singapore, Indonesia, Thailand and Australia SMEQ: China (i) TRSB's responsibility and contribution TRSB shall be responsible in the area of medical related real estate by providing infrastructures, land and facilities for the medical operators recommended by Sinopharm Group or SMEQ pertaining to the New Business. (ii) SMEQ's responsibility and contribution SMEQ undertakes to supply the medical and hospital equipment and products under the New Business as set out in the Strategic Collaboration Agreement I. Strategic Collaboration Agreement II (i) TRSB's responsibility and contribution TRSB undertakes to provide funding to meet the financing conditions for the construction base and be responsible for the related development and construction conditions of the construction base for the purpose of the New Business as set out in Strategic Collaboration Agreement II. (ii) SINOMACH's responsibility and contribution SINOMACH undertakes to assist TRSB in sourcing for funding, and to provide resources in any manners, at the construction base, for the supply of equipment, technological and technical support for the New Business. Strategic Collaboration Agreement III Rubberex shall sell, and TRSB shall buy gloves from Rubberex, and export to the China market via SMEQ. Further, TRSB shall distribute and import the personal protection equipment and medical products from SMEQ, and sell to Rubberex. The Board anticipates that the net profit attributable to the New Business may contribute more than 25.0% of the total net profit of Titijaya Group in the financial years moving forward. Accordingly, the Board proposes to seek for the approval from the shareholders of Titijaya at an extraordinary general meeting ("EGM") to be convened for the Proposed Diversification pursuant to Paragraph 10.13(1) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") ("Listing Requirements"). Notwithstanding the Proposed Diversification, the Board intends to continue with the existing business activities of Titijaya Group in the same manner
@scenery, it already higher than usual, trend supposedly ongoing but UMA ruin it all, making retailers lose confidence. Btw,is this the first time market crash to this level on 2020 or its already happening earlier month? I'm new to bursa.
I bought back today at 0.50. Yesterday I mentioned that this counter need to fall below 0.50 below it can rise. So it hit low of 0.475, so time to take position.
this is one risky counter while most health glve related penny counter already drop near to their original price (ie esceram luxceram etc) this counter still got potential to lost another 20+ cents to reach 26-30 cents range..
This counter is different compare to others pennies counter. .Titijaya did right, first trade and distribute , exposure to market . Buy from existing manufacturers like Rubberex. Many local manufacturers are OEM to big cooperation. And Titijaya have strong China partner. And at the meantime, on machine and production line planning. And they are not only limit to glove but more on other healthcare products , looking at long term future. The plan is acceptable
JK22, agree with you. One observation was that, after Titijaya announced they have signed JV agreement with Sinopharm, the Govt later announced they will also work with China side on the vaccine supply and distribution. The player that can stay one step ahead will be the winner. I think Titijaya has the potential to do that.
kkwn with the agreement signed with Sinopharm, I think the chances is high that TTJY will be successful to venture into the vaccine distribution. Dealing with China is not an easy thing, everything gotta move fast, cheap and effecient. Our GLCs carry too much baggages.
Putting Vaccine a side ,for long tem, if Titijaya (TRSB) could act as an international procurement centre for others health products will be a good diversification from being just a developer . We don't know what is their plan or market opportunity. We can only hope they work out well.
Agree actually TRSB is moving one step ahead of the trend by setting up an integrated centre for healthcare based products.The potential is explosive because it can be the regional One-Stop Centre for all health related products including vaccines.
with above agreement, they should be able to supply gloves immediately to China. right? China need a lots of Gloves and Malaysian's gloves manufacturing is famouns in the world.
whereby other companies need to build factory first then only can supply gloves. so we will see TTJY much better prospect than others which have nothing and their share prices goes up many folds.
From chart, Titijaya no doubt looks vulnerable as it may retest its support level at around 0.35 but this also represents a fantastic opportunity to buy more
I’m waiting to buy more if it drops. Long term investors should take this opportunity to add exposure too
Soon the market theme would strongly shift towards vaccine and Covid19 drugs theme. TRSB has oredi positioned itself at this early stage. There maybe other players trying to copycat their concept, including some GLCs. But the signing with Sinopharm at this early stage will give TRSB a head start.
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Friendship
1,616 posts
Posted by Friendship > 2020-08-13 21:26 | Report Abuse
https://www.nst.com.my/news/nation/2020/07/612266/khairy-not-limited-pharmaniaga-and-duopharma-nsttv
Khairy: 'Not limited to Pharmaniaga and Duopharma' [NSTTV]